Bioartificial kidney gets its “living membrane”

Researchers have come one step closer to developing a bioartificial kidney by producing the “living membrane” portion of the kidney. The latest in the development is set to be presented at American Society of Nephrology (ASN) Kidney Week 2016.

For the millions of patients suffering from renal failure, the only approach to treatment is waiting on the donor list while undergoing dialysis. In an effort to expand methods of treatment, researchers have begun to develop a bioartificial kidney. Building a kidney is easier said than done, though, and development takes innovation, investment and time.

Lead by Dimitrios Stamatialis, PhD, of the Netherlands' University of Twente, and Roos Masereeuw, PhD, of the University of Utrecht, also in the Netherlands, the team of researchers have developed a major piece to the bioartificial kidney puzzle. The development of the “living membrane," the cell layer of the kidney on an artificial membrane that transports molecules. Using conditionally immortalized human renal proximal tubular epithelial cells (ciPTEC) on polyethersulfone-based hollow fiber membranes, the membrane functions as the “living membrane” of the kidney.

"This study shows the successful development of a living membrane consisting of a reproducible ciPTEC monolayer on hollow fiber membranes, an important step towards the development of a bioartificial kidney device," said Stamatialis. "The strategies and methods of this work could be relevant to the development of other bioartificial organs, such as a bioartificial liver or bioartificial pancreas, and organs on chips—such as a kidney on chip, a lung on chip or a liver on chip."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”